Price T Rowe Associates Inc Ascendis Pharma A/S Call Options Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ASND
# of Institutions
228Shares Held
56.6MCall Options Held
142KPut Options Held
259K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.31 Billion20.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.96MShares$642 Million3.41% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.3MShares$556 Million0.93% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.2MShares$543 Million7.81% of portfolio
-
Janus Henderson Group PLC London, X03.92MShares$507 Million0.29% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.22B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...